Citi analyst Joanne Wuensch upgraded Silk Road Medical to Neutral from Sell with an unchanged price target of $50. The stock has fallen 16% since the company reported Q4 results while its 2023 guidance is realistic, the analyst tells investors in a research note. The firm cites the recent pullback in the shares for the upgrade.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical reports Q4 EPS (34c), consensus (38c)
- Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook
- Silk Road Medical to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
- Silk Road Medical downgraded to Peer Perform from Outperform at Wolfe Research
